[1]《型糖尿病短期胰岛素强化治疗专家共识》编写委员会.2型糖尿病短期胰岛素强化治疗专家共识(2021年版)[J].国际内分泌代谢杂志,2022,42(01):67-77.[doi:10.3760/cma.j.cn121383-20220114-01028]
点击复制

2型糖尿病短期胰岛素强化治疗专家共识(2021年版)()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年01期
页码:
67-77
栏目:
指南与共识
出版日期:
2022-01-20

文章信息/Info

Title:
Expert consensus on short-term insulin intensive therapy for type 2 diabetes mellitus(2021 edition)Expert Consensus on Short-term Insulin Intensive Therapy for Type 2 Diabetes Mellitus Writing Group
作者:
《2型糖尿病短期胰岛素强化治疗专家共识》编写委员会
关键词:
糖尿病; 2型;  短期胰岛素强化治疗;  专家共识
DOI:
10.3760/cma.j.cn121383-20220114-01028
摘要:
短期胰岛素强化治疗是强化血糖控制的重要方法之一,适用于糖化血红蛋白≥9.0%或空腹血糖≥11.1 mmol/L,或伴有明显高血糖症状的新诊断2型糖尿病患者,以及已经使用多种口服降糖药联合治疗3个月以上血糖仍明显升高(如糖化血红蛋白≥9.0%),或使用胰岛素治疗并经过充分的剂量调整血糖仍未达标的2型糖尿病患者。实施短期胰岛素强化治疗有助于快速减轻高糖毒性,改善患者预后。从事相关内容研究的内分泌专家组成了《2型糖尿病短期胰岛素强化治疗专家共识》编写委员会,以2017年《2型糖尿病短期胰岛素强化治疗临床专家指导意见》为基础,结合最新的循证医学证据和研究新进展,形成了《2型糖尿病短期胰岛素强化治疗专家共识(2021年版)》。内容涵盖短期胰岛素强化治疗的定义和临床获益、治疗的适用人群、血糖控制目标和治疗方案、短期胰岛素强化治疗的后续血糖管理、2型糖尿病特殊人群的短期胰岛素治疗注意事项、低血糖发生的原因及对策等,并给出了2型糖尿病患者的短期胰岛素强化治疗路径,以期指导临床治疗,使患者获益。

参考文献/References:

[1] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33).UK Prospective Diabetes Study(UKPDS)Group[J].Lancet,1998,352(9131):837-853.
[2] ADVANCE Collaborative Group,Patel A,MacMahon S,et al.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[J].N Engl J Med,2008,358(24):2560-2572.DOI:10.1056/NEJMoa0802987.
[3] Duckworth W,Abraira C,Moritz T,et al.Glucose control and vascular complications in veterans with type 2 diabetes[J].N Engl J Med,2009,360(2):129-139.DOI:10.1056/NEJMoa0808431.
[4] ORIGIN Trial Investigators,Gerstein HC,Bosch J,et al.Basal insulin and cardiovascular and other outcomes in dysglycemia[J].N Engl J Med,2012,367(4):319-328.DOI:10.1056/NEJMoa1203858.
[5] Turnbull FM,Abraira C,Anderson RJ,et al.Intensive glucose control and macrovascular outcomes in type 2 diabetes[J].Diabetologia,2009,52(11):2288-2298.DOI:10.1007/s00125-009-1470-0.
[6] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.DOI:10.3760/cma.j.cn115791-20210221-00095.
[7] 李延兵,马建华,母义明.2型糖尿病短期胰岛素强化治疗临床专家指导意见[J].药品评价,2017,14(9):5-12,26.DOI:10.3969/j.issn.1672-2809.2017.09.001.
[8] Weng J,Li Y,Xu W,et al.Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes:a multicentre randomised parallel-group trial[J].Lancet,2008,371(9626):1753-1760.DOI:10.1016/S0140-6736(08)60762-X.
[9] Li Y,Xu W,Liao Z,et al.Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function[J].Diabetes Care,2004,27(11):2597-2602.DOI:10.2337/diacare.27.11.2597.
[10] Kramer CK,Zinman B,Retnakaran R.Short-term intensive insulin therapy in type 2 diabetes mellitus:a systematic review and meta-analysis[J].Lancet Diabetes Endocrinol,2013,1(1):28-34.DOI:10.1016/S2213-8587(13)70006-8.
[11] Stein CM,Kramer CK,Zinman B,et al.Clinical predictors and time course of the improvement in β-cell function with short-term intensive insulin therapy in patients with Type 2 diabetes[J].Diabet Med,2015,32(5):645-652.DOI:10.1111/dme.12671.
[12] Wang H,Kuang J,Xu M,et al.Predictors of long-term glycemic remission after 2-week intensive insulin treatment in newly diagnosed type 2 diabetes[J].J Clin Endocrinol Metab,2019,104(6):2153-2162.DOI:10.1210/jc.2018-01468.
[13] 刘娟,Jasmeen Tuladhar,柯伟健,等.短期胰岛素泵强化治疗期间2型糖尿病患者胰岛功能变化对预后的影响[J].中华糖尿病杂志,2014,6(5):293-298.DOI:10.3760/cma.j.issn.1674-5809.2014.05.005.
[14] Liu L,Yang S,Liu J,et al.Fasting plasma glucose indicates reversibility of the acute insulin response after short-term intensive insulin therapy in patients with various duration of type 2 Diabetes[J].J Diabetes Res,2018,2018:9423965.DOI:10.1155/2018/9423965.
[15] 李延兵,曾龙驿,时立新,等.早期强化治疗对不同血糖水平新诊断2型糖尿病患者胰岛β细胞功能和预后的影响[J].中华内科杂志,2010,49(1):9-13.DOI:10.3760/cma.j.issn.0578-1426.2010.01.004.
[16] Liu L,Liu J,Xu L,et al.Lower mean blood glucose during short-term intensive insulin therapy is associated with long-term glycemic remission in patients with newly diagnosed type 2 diabetes:evidence-based recommendations for standardization[J].J Diabetes Investig,2018,9(4):908-916.DOI:10.1111/jdi.12782.
[17] Battelino T,Danne T,Bergenstal RM,et al.Clinical targets for continuous glucose monitoring data interpretation:recommendations from the international consensus on time in range[J].Diabetes Care,2019,42(8):1593-1603.DOI:10.2337/dci19-0028.
[18] Liu LH,Xu LJ,Ke WJ,et al.Time-in-range during short-term intensive insulin therapy is associated with clinical outcomes in patients with newly diagnosed type 2 diabetes[J].Diabetes,2020,69 Suppl 1:1032.DOI:10.2337/db20-1032-P.
[19] Reznik Y,Cohen O,Aronson R,et al.Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes(OpT2mise):a randomised open-label controlled trial[J].Lancet,2014,384(9950):1265-1272.DOI:10.1016/S0140-6736(14)61037-0.
[20] Pickup JC,Reznik Y,Sutton AJ.Glycemic control during continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes:individual patient data meta-analysis and meta-regression of randomized controlled trials[J].Diabetes Care,2017,40(5):715-722.DOI:10.2337/dc16-2201.
[21] Garber AJ,King AB,Del Prato S,et al.Insulin degludec,an ultra-longacting basal insulin,versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes(BEGIN Basal-Bolus Type 2):a phase 3,randomised,open-label,treat-to-target non-inferiority trial[J].Lancet,2012,379(9825):1498-1507.DOI:10.1016/S0140-6736(12)60205-0.
[22] Suzuki J,Yamakawa T,Oba M,et al.Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes:an open-label,randomized controlled study[J].Endocr J,2019,66(11):971-982.DOI:10.1507/endocrj.EJ18-0309.
[23] Yang W,Ji Q,Zhu D,et al.Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen,without increasing hypoglycemia,in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs[J].Diabetes Care,2008,31(5):852-856.DOI:10.2337/dc07-1992.
[24] Jia W,Xiao X,Ji Q,et al.Comparison of thrice-daily premixed insulin(insulin lispro premix)with basal-bolus(insulin glargine once-daily plus thrice-daily prandial insulin lispro)therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin:an open-label,randomised,controlled trial[J].Lancet Diabetes Endocrinol,2015,3(4):254-262.DOI:10.1016/S2213-8587(15)00041-8.
[25] Hakoshima M,Yanai H,Kakuta K,et al.Sodium-glucose cotransporter 2 inhibitors reduce prandial insulin doses in type 2 diabetic patients treated with the intensive insulin therapy[J].J Clin Med Res,2018,10(6):493-498.DOI:10.14740/jocmr3392w.
[26] Li FF,Liu BL,Yin GP,et al.Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes[J].Sci Rep,2018,8(1):9713.DOI:10.1038/s41598-018-27950-9.
[27] Li LQ,Yao MY,Ma JX,et al.Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus:a study based on the flash glucose monitoring system[J].Endocr J,2019,66(10):871-880.DOI:10.1507/endocrj.EJ19-0016.
[28] 李晓静,高政南,程丽静,等.采用CGMS评价阿卡波糖对胰岛素治疗血糖波动的影响[J].中华内分泌代谢杂志,2012,28(2):140-143.DOI:10.3760/cma.j.issn.1000-6699.2012.02.013.
[29] 中华医学会内分泌学分会,中华医学会糖尿病学分会,中国医师协会内分泌代谢科医师分会.中国胰岛素泵治疗指南(2021年版)[J].中华内分泌代谢杂志,2021,37(8):679-701.DOI:10.3760/cma.j.cn311282-20210428-00265.
[30] 中华医学会内分泌学分会.预混胰岛素临床应用专家共识(2016年版)[J].药品评价,2016,13(9):5-11.DOI:10.3969/j.issn.1672-2809.2016.09.002.
[31] Park S,Choi SB.Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy[J].Diabetes Metab Res Rev,2003,19(2):124-130.DOI:10.1002/dmrr.343.
[32] Chen A,Huang Z,Wan X,et al.Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment[J].Diabetes Care,2012,35(3):474-481.DOI:10.2337/dc11-1638.
[33] Xu L,Wang L,Huang X,et al.Baseline red blood cell distribution width predicts long-term glycemic remission in patients with type 2 diabetes[J].Diabetes Res Clin Pract,2017,131:33-41.DOI:10.1016/j.diabres.2017.06.019.
[34] Liu L,Ke W,Wan X,et al.Insulin requirement profiles of short-term intensive insulin therapy in patients with newly diagnosed type 2 diabetes and its association with long-term glycemic remission[J].Diabetes Res Clin Pract,2015,108(2):250-257.DOI:10.1016/j.diabres.2015.02.011.
[35] Liu J,Liu J,Fang D,et al.Fasting plasma glucose after intensive insulin therapy predicted long-term glycemic control in newly diagnosed type 2 diabetic patients[J].Endocr J,2013,60(6):725-732.DOI:10.1507/endocrj.ej12-0315.
[36] Liu L,Wan X,Liu J,et al.Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy[J].Diabetes Technol Ther,2012,14(9):756-761.DOI:10.1089/dia.2012.0055.
[37] 杨彩娴,黄启亚,钟国权,等.新诊断2型糖尿病早期胰岛素强化治疗后三种治疗方案对胰岛β细胞功能及胰岛素抵抗的影响[J].中华糖尿病杂志,2016,8(10):613-617.DOI:10.3760/cma.j.issn.1674-5809.2016.10.009.
[38] Cheng Q,Yang S,Zhao C,et al.Efficacy of metformin-based oral antidiabetic drugs is not inferior to insulin glargine in newly diagnosed type 2 diabetic patients with severe hyperglycemia after short-term intensive insulin therapy[J].J Diabetes,2015,7(2):182-191.DOI:10.1111/1753-0407.12167.
[39] Fujiwara D,Takahashi K,Suzuki T,et al.Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection:Analysis of C-peptide values before and after short-term intensive insulin therapy[J].J Diabetes Investig,2013,4(6):618-625.DOI:10.1111/jdi.12103.
[40] 《2型糖尿病起始胰岛素后方案转换的临床指导建议》编写委员会.2型糖尿病起始胰岛素后方案转换的临床指导建议[J].中华糖尿病杂志,2018,10(2):97-102.DOI:10.3760/cma.j.issn.1674-5809.2018.02.001.
[41] Dupuy O,Mayaudon H,Palou M,et al.Optimized transient insulin infusion in uncontrolled type 2 diabetes:evaluation of a pragmatic attitude[J].Diabetes Metab,2000,26(5):371-315.
[42] Suzuki T,Takahashi K,Fujiwara D,et al.A reliable serum C-peptide index for the selection of an insulin regimen to achieve good glycemic control in obese patients with type 2 diabetes:an analysis from a short-term study with intensive insulin therapy[J].Diabetol Int,2016,7(3):235-243.DOI:10.1007/s13340-015-0239-6.
[43] Yamamoto Y,Takahara M,Yasuda T,et al.Predictive factors for the efficacy of switch to oral hypoglycemic agents in Japanese type 2 diabetic patients with intensive insulin therapy temporarily introduced[J].Endocr J,2014,61(9):911-919.DOI:10.1507/endocrj.ej14-0011.
[44] Mu PW,Liu DZ,Lin Y,et al.The postprandial-to-fasting serum C-Peptide ratio is a predictor of response to basal insulin-supported oral antidiabetic drug(s)therapy:a retrospective analysis[J].Diabetes Ther,2018,9(3):963-971.DOI:10.1007/s13300-018-0404-6.
[45] Yoshihara T,Kumashiro N,Kanazawa Y,et al.Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus[J].Endocr J,2006,53(1):67-72.DOI:10.1507/endocrj.53.67.
[46] Price H,Blüher M,Prager R,et al.Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide(IDegLira)in a real-world population with type 2 diabetes:Results from a European,multicentre,retrospective chart review study[J].Diabetes Obes Metab,2018,20(4):954-962.DOI:10.1111/dom.13182.
[47] Li CJ,Li J,Zhang QM,et al.Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity[J].Cardiovasc Diabetol,2012,11:142.DOI:10.1186/1475-2840-11-142.
[48] Billings LK,Doshi A,Gouet D,et al.Efficacy and safety of ideglira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin:the DUAL VII randomized clinical trial[J].Diabetes Care,2018,41(5):1009-1016.DOI:10.2337/dc17-1114.
[49] Aroda VR,Rosenstock J,Wysham C,et al.Efficacy and safety of lixilan,a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin:the lixilan-l randomized trial[J].Diabetes Care,2016,39(11):1972-1980.DOI:10.2337/dc16-1495.
[50] 朱大龙,赵维纲,匡洪宇,等.德谷门冬双胰岛素临床应用专家指导意见[J].中华糖尿病杂志,2021,13(7):695-701.DOI:10.3760/cma.j.cn115791-20210506-00247.
[51] American Diabetes Association.Introduction:standards of medical care in diabetes-2021[J].Diabetes Care,2021,44 Suppl 1:S1-S2.DOI:10.2337/dc21-Sint.
[52] 国家老年医学中心,中华医学会老年医学分会,中国老年保健协会糖尿病专业委员会.中国老年糖尿病诊疗指南(2021年版)[J].中华糖尿病杂志,2021,13(1):14-46.DOI:10.3760/cma.j.cn115791-20201209-00707.

相似文献/References:

[1]郑少雄.罗格列酮和心血管风险——近期文献解读[J].国际内分泌代谢杂志,2007,(04):231.
[2]凌厉,朱本章.胰岛素类似物安全性研究进展[J].国际内分泌代谢杂志,2007,(04):234.
[3]李颖,刘东方.餐后1小时血糖升高的意义及干预[J].国际内分泌代谢杂志,2007,(04):235.
[4]崔巍,施秉银.内质网应激介导β细胞生存/死亡的研究进展[J].国际内分泌代谢杂志,2007,(04):256.
[5]杨叶虹,胡仁明.SELDI-TOF-MS技术及其在糖尿病研究中的应用[J].国际内分泌代谢杂志,2007,(04):261.
[6]高妍.针对华人糖尿病特点优化降糖方案[J].国际内分泌代谢杂志,2007,(04):269.
[7]杨志霞,郭莹辉,杨永生,等.胰岛素泵和多次皮下注射治疗糖尿病的比较[J].国际内分泌代谢杂志,2007,(04):273.
[8]周建英,马向华.胃旁路术减肥同时改善糖代谢的机制[J].国际内分泌代谢杂志,2007,(04):285.
[9]李翠柳,朱大龙.破译肠道代谢信息,驱动治疗革新[J].国际内分泌代谢杂志,2014,(06):383.[doi:10.3760/cma.j.issn.1673-4157.2014.06.006]
　Li Cuiliu*,Zhu Dalong..Deciphering metabolic messages from the gut drives therapeutic innovation[J].International Journal of Endocrinology and Metabolism,2014,(01):383.[doi:10.3760/cma.j.issn.1673-4157.2014.06.006]
[10]袁捷 姜云生 杜彦丽 王肃.1型糖尿病对小鼠早孕时期子宫肌层结构和细胞增殖的影响[J].国际内分泌代谢杂志,2015,(01):6.[doi:10.3760/cma.j.issn.1673-4157.2015.01.002]
　Yuan JieJiang YunshengDu YanliWang Su.Effects of type 1 diabetes on the muscularis structure and cell proliferation of uterine in mice during early pregnancy[J].International Journal of Endocrinology and Metabolism,2015,(01):6.[doi:10.3760/cma.j.issn.1673-4157.2015.01.002]
[11]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].国际内分泌代谢杂志,2021,41(05):482.[doi:10.3760/cma.j.cn121383-20210825-08063]
[12]姬秋和 陈莉明 郗光霞 余学锋 洪天配 邹大进 秦贵军7 杨刚毅8.2型糖尿病患者体重管理专家共识[J].国际内分泌代谢杂志,2022,42(01):78.[doi:10.3760/cma.j.cn121383-20211102-11004]
　Ji Qiuhe,Chen Liming,Xi Guangxia,et al.Expert consensus on weight management for type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2022,42(01):78.[doi:10.3760/cma.j.cn121383-20211102-11004]

备注/Memo

备注/Memo:
通信作者:李延兵,中山大学附属第一医院内分泌科,广州 510080,Email:liyb@mail.sysu.edu.cn; 母义明,解放军总医院第一医学中心内分泌科,北京 100853,Email:muyiming@301hospital.com.cn; 朱大龙,南京大学医学院附属鼓楼医院内分泌科 210008,Email:zhudalong@nju.edu.cn
更新日期/Last Update: 2022-01-20